TWI455939B - cMET抑制劑 - Google Patents
cMET抑制劑 Download PDFInfo
- Publication number
- TWI455939B TWI455939B TW098127469A TW98127469A TWI455939B TW I455939 B TWI455939 B TW I455939B TW 098127469 A TW098127469 A TW 098127469A TW 98127469 A TW98127469 A TW 98127469A TW I455939 B TWI455939 B TW I455939B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- methyl
- pharmaceutically acceptable
- compound
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Claims (6)
- 一種具有下列分子式的化合物: 或其一藥學上可接受的鹽類,其中R1 具有該分子式 R19 是環丙基;R10 是選自由氫、鹵素、甲基、-CF3 、氰基、經0、1、2、3、 4或5個R20b 取代之苯基、式之基團及式之基團所組成的群組,其中R20b 是獨立地選自氫、(C1-5 )烷基、苯基、(C3-12 )環烷基、雜(C4-10 )芳基、羥(C1-6 )烷基及鹵素所組成的群組;或其藥學上可接受鹽類。
- 如申請專利範圍第1項的化合物,其中R20b 是氫。
- 如申請專利範圍第1項的化合物,其中R20b 是甲基。
- 如申請專利範圍第1項的化合物,其選自由以下組成的群組:N-(6-(二氟(6-(1-(2-羥乙基)-1H-吡唑-4-基)-[1,2,4]三唑並[4,3-a]吡啶-3-基)甲基)咪唑[1,2-b]噠嗪-2-基)環丙烷甲醯胺;及 N-(6-((6-(1H-吡唑-4-基)-[1,2,4]三唑並[4,3-a]吡啶-3-基)二氟甲基)咪唑[1,2-b]噠嗪-2-基)環丙烷甲醯胺;或其藥學上可接受之鹽類。
- 如申請專利範圍第1項的化合物,其中該化合物是N-(6-(二氟(6-(1-甲基-1H-吡唑-4-基)-[1,2,4]三唑並[4,3-a]吡啶-3-基)甲基)咪唑[1,2-b]噠嗪-2-基)環丙烷甲醯胺,或其藥學上可接受之鹽類。
- 一種藥學組成物,其包含如申請專利範圍第1至5項中任一項的化合物;以及一藥學上可接受的賦形劑。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8895908P | 2008-08-14 | 2008-08-14 | |
US11791008P | 2008-11-25 | 2008-11-25 | |
US16100709P | 2009-03-17 | 2009-03-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201014857A TW201014857A (en) | 2010-04-16 |
TWI455939B true TWI455939B (zh) | 2014-10-11 |
Family
ID=41202532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW098127469A TWI455939B (zh) | 2008-08-14 | 2009-08-14 | cMET抑制劑 |
Country Status (26)
Country | Link |
---|---|
US (1) | US8178534B2 (zh) |
EP (1) | EP2313407B1 (zh) |
JP (1) | JP5469666B2 (zh) |
KR (1) | KR20110039383A (zh) |
CN (1) | CN102124005B (zh) |
AR (1) | AR072936A1 (zh) |
AU (1) | AU2009281822B2 (zh) |
BR (1) | BRPI0917808A2 (zh) |
CA (1) | CA2731108A1 (zh) |
CO (1) | CO6351724A2 (zh) |
CR (1) | CR20110135A (zh) |
DO (1) | DOP2011000050A (zh) |
EA (1) | EA019723B1 (zh) |
EC (1) | ECSP11010889A (zh) |
ES (1) | ES2608761T3 (zh) |
GE (1) | GEP20125652B (zh) |
IL (1) | IL210734A0 (zh) |
MA (1) | MA32615B1 (zh) |
MX (1) | MX2011001732A (zh) |
MY (1) | MY150542A (zh) |
NZ (1) | NZ590617A (zh) |
PE (1) | PE20110275A1 (zh) |
TW (1) | TWI455939B (zh) |
UY (1) | UY32049A (zh) |
WO (1) | WO2010019899A1 (zh) |
ZA (1) | ZA201100467B (zh) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
US20090197880A1 (en) * | 2007-07-13 | 2009-08-06 | Genelabs Technologies, Inc. | Anti-viral compounds, compositions, and methods of use |
EP2200985B1 (en) | 2007-09-14 | 2011-07-13 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
AU2008297877C1 (en) | 2007-09-14 | 2013-11-07 | Addex Pharma S.A. | 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones |
CN101801951B (zh) | 2007-09-14 | 2013-11-13 | 杨森制药有限公司 | 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮 |
CN101861316B (zh) | 2007-11-14 | 2013-08-21 | 奥梅-杨森制药有限公司 | 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
JPWO2009128520A1 (ja) * | 2008-04-18 | 2011-08-04 | 塩野義製薬株式会社 | Pi3k阻害活性を有する複素環化合物 |
ES2439291T3 (es) | 2008-09-02 | 2014-01-22 | Janssen Pharmaceuticals, Inc. | Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos |
JP5656848B2 (ja) | 2008-10-16 | 2015-01-21 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体 |
US8691813B2 (en) | 2008-11-28 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
MX2011011962A (es) | 2009-05-12 | 2012-02-28 | Janssen Pharmaceuticals Inc | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2). |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
ME01573B (me) | 2009-05-12 | 2014-09-20 | Addex Pharma Sa | DERIVATI 1,2,4-TRIAZOLO[4,3-a]PIRIDINA I NJIHOVA UPOTREBA U TRETMANU ILI PREVENCIJI NEUROLOŠKIH I PSIHIJATRIJSKIH POREMEĆAJA |
EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
HRP20221090T1 (hr) | 2009-12-31 | 2022-11-25 | Hutchison Medipharma Limited | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe |
DK2571878T3 (en) * | 2010-05-17 | 2019-02-11 | Indian Incozen Therapeutics Pvt Ltd | Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES |
WO2012003338A1 (en) * | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
AU2011328195B2 (en) | 2010-11-08 | 2015-04-02 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
US9271967B2 (en) | 2010-11-08 | 2016-03-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
CN103958509B (zh) * | 2011-09-15 | 2015-12-23 | 诺华股份有限公司 | 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物 |
CN103030654A (zh) * | 2011-10-09 | 2013-04-10 | 济南赛文医药技术有限公司 | 一种小分子c-Met蛋白激酶抑制剂 |
WO2013135674A1 (en) * | 2012-03-12 | 2013-09-19 | Syngenta Participations Ag | Insecticidal 2-aryl-acetamide compounds |
PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
CN105143228B (zh) * | 2013-05-10 | 2017-07-21 | 江苏豪森药业集团有限公司 | [1,2,4]三唑并[4,3‑a]吡啶类衍生物,其制备方法或其在医药上的应用 |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
EP2818471A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
PL3096790T3 (pl) | 2014-01-21 | 2020-01-31 | Janssen Pharmaceutica, N.V. | Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie |
KR20200036063A (ko) | 2014-01-21 | 2020-04-06 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
US9493442B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
PL3105218T3 (pl) | 2014-02-13 | 2020-03-31 | Incyte Corporation | Cyklopropyloaminy jako inhibitory lsd1 |
LT3105226T (lt) | 2014-02-13 | 2019-11-11 | Incyte Corp | Ciklopropilaminai, kaip lsd1 inhibitoriai |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
CN113004278B (zh) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
SG10201912684TA (en) * | 2015-06-25 | 2020-03-30 | Taiho Pharmaceutical Co Ltd | Therapeutic agent for fibrosis |
SG10202001219UA (en) | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
CN106924260B (zh) * | 2015-12-31 | 2018-05-25 | 北京浦润奥生物科技有限责任公司 | 化合物在制备用于治疗脑胶质瘤的药物中的用途 |
WO2017136727A2 (en) | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
PE20190377A1 (es) | 2016-04-22 | 2019-03-08 | Incyte Corp | Formulaciones de un inhibidor de lsd 1 |
US10765116B2 (en) | 2016-11-23 | 2020-09-08 | Bayer Cropscience Aktiengesellschaft | 2-[3-(alkylsulfonyl)-2H-indazol-2-yl]-3H-imidazo[4,5-B]pyridine derivatives and similar compounds as pesticides |
ES2912295T3 (es) | 2016-12-09 | 2022-05-25 | Denali Therapeutics Inc | Compuestos útiles como inhibidores de RIPK1 |
EP3583943A4 (en) | 2017-02-15 | 2020-12-30 | Taiho Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
US11396502B2 (en) | 2018-11-13 | 2022-07-26 | Incyte Corporation | Substituted heterocyclic derivatives as PI3K inhibitors |
US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
WO2020102198A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
WO2020124060A1 (en) | 2018-12-14 | 2020-06-18 | Beta Pharma, Inc. | Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
TW202128685A (zh) | 2019-10-14 | 2021-08-01 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
TW202334164A (zh) | 2022-01-12 | 2023-09-01 | 美商戴納立製藥公司 | (S)-5-苄基-N-(5-甲基-4-側氧基-2,3,4,5-四氫吡啶並[3,2-b][1,4]氧氮呯-3-基)-4H-1,2,4-三唑-3-甲醯胺的晶型 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200801007A (en) * | 2005-12-21 | 2008-01-01 | Janssen Pharmaceutica Nv | Triazolopyridazines as kinase modulators |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8719368D0 (en) * | 1987-08-15 | 1987-09-23 | Wellcome Found | Heterocyclic compounds |
US7723336B2 (en) * | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
WO2007064797A2 (en) | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
US8044049B2 (en) | 2006-08-04 | 2011-10-25 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
TW200817410A (en) * | 2006-08-07 | 2008-04-16 | Incyte Corp | Triazolotriazines as kinase inhibitors |
EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
WO2008030579A2 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
DK2084162T3 (da) | 2006-10-23 | 2012-10-01 | Sgx Pharmaceuticals Inc | Bicykliske triazoler som proteinkinasemodulatorer |
ME02372B (me) * | 2006-11-22 | 2016-06-20 | Incyte Holdings Corp | Imidazotriazini i imidazopiramidini kao inhibitori kinaze |
PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
PE20091468A1 (es) * | 2008-02-28 | 2009-10-22 | Novartis Ag | DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA |
-
2009
- 2009-08-13 UY UY0001032049A patent/UY32049A/es not_active Application Discontinuation
- 2009-08-14 TW TW098127469A patent/TWI455939B/zh not_active IP Right Cessation
- 2009-08-14 GE GEAP200912126A patent/GEP20125652B/en unknown
- 2009-08-14 MY MYPI20110564 patent/MY150542A/en unknown
- 2009-08-14 US US12/541,724 patent/US8178534B2/en not_active Expired - Fee Related
- 2009-08-14 MX MX2011001732A patent/MX2011001732A/es active IP Right Grant
- 2009-08-14 EP EP09791542.5A patent/EP2313407B1/en active Active
- 2009-08-14 JP JP2011523198A patent/JP5469666B2/ja not_active Expired - Fee Related
- 2009-08-14 BR BRPI0917808A patent/BRPI0917808A2/pt not_active IP Right Cessation
- 2009-08-14 AR ARP090103156A patent/AR072936A1/es unknown
- 2009-08-14 WO PCT/US2009/053913 patent/WO2010019899A1/en active Application Filing
- 2009-08-14 AU AU2009281822A patent/AU2009281822B2/en not_active Expired - Fee Related
- 2009-08-14 PE PE2011000152A patent/PE20110275A1/es not_active Application Discontinuation
- 2009-08-14 KR KR1020117005243A patent/KR20110039383A/ko not_active Application Discontinuation
- 2009-08-14 CA CA2731108A patent/CA2731108A1/en not_active Abandoned
- 2009-08-14 CN CN200980131456.9A patent/CN102124005B/zh not_active Expired - Fee Related
- 2009-08-14 ES ES09791542.5T patent/ES2608761T3/es active Active
- 2009-08-14 NZ NZ590617A patent/NZ590617A/en not_active IP Right Cessation
- 2009-08-14 EA EA201170295A patent/EA019723B1/ru not_active IP Right Cessation
-
2011
- 2011-01-18 IL IL210734A patent/IL210734A0/en unknown
- 2011-01-18 ZA ZA2011/00467A patent/ZA201100467B/en unknown
- 2011-02-11 DO DO2011000050A patent/DOP2011000050A/es unknown
- 2011-03-07 MA MA33676A patent/MA32615B1/fr unknown
- 2011-03-11 CO CO11030354A patent/CO6351724A2/es active IP Right Grant
- 2011-03-14 CR CR20110135A patent/CR20110135A/es unknown
- 2011-03-14 EC EC2011010889A patent/ECSP11010889A/es unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200801007A (en) * | 2005-12-21 | 2008-01-01 | Janssen Pharmaceutica Nv | Triazolopyridazines as kinase modulators |
Also Published As
Publication number | Publication date |
---|---|
CA2731108A1 (en) | 2010-02-18 |
KR20110039383A (ko) | 2011-04-15 |
BRPI0917808A2 (pt) | 2019-09-24 |
ECSP11010889A (es) | 2011-04-29 |
IL210734A0 (en) | 2011-03-31 |
JP5469666B2 (ja) | 2014-04-16 |
CR20110135A (es) | 2011-09-27 |
MX2011001732A (es) | 2011-03-25 |
EP2313407A1 (en) | 2011-04-27 |
AU2009281822B2 (en) | 2014-11-13 |
EP2313407B1 (en) | 2016-10-05 |
EA201170295A1 (ru) | 2011-08-30 |
PE20110275A1 (es) | 2011-05-08 |
TW201014857A (en) | 2010-04-16 |
GEP20125652B (en) | 2012-09-25 |
JP2012500215A (ja) | 2012-01-05 |
NZ590617A (en) | 2012-05-25 |
CN102124005A (zh) | 2011-07-13 |
WO2010019899A1 (en) | 2010-02-18 |
CO6351724A2 (es) | 2011-12-20 |
MY150542A (en) | 2014-01-30 |
AU2009281822A1 (en) | 2010-02-18 |
EA019723B1 (ru) | 2014-05-30 |
US20100063054A1 (en) | 2010-03-11 |
MA32615B1 (fr) | 2011-09-01 |
CN102124005B (zh) | 2014-06-04 |
DOP2011000050A (es) | 2011-03-15 |
AR072936A1 (es) | 2010-09-29 |
UY32049A (es) | 2010-03-26 |
US8178534B2 (en) | 2012-05-15 |
ZA201100467B (en) | 2012-03-28 |
ES2608761T3 (es) | 2017-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI455939B (zh) | cMET抑制劑 | |
JP2008517913A5 (zh) | ||
NZ599932A (en) | Imidazopyridine derivatives as jak inhibitors | |
JP2013510124A5 (zh) | ||
HRP20150868T1 (hr) | Derivati kinolina i kinoksalina kao inhibitori kinaze | |
JP2013529196A5 (zh) | ||
WO2011113802A3 (en) | Imidazopyridine and purine compounds, compositions and methods of use | |
JP2014526549A5 (zh) | ||
JP2010502751A5 (zh) | ||
JP2015506348A5 (zh) | ||
JP2013510120A5 (zh) | ||
RU2672910C2 (ru) | Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы | |
NZ608718A (en) | Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors | |
JP2013528204A5 (zh) | ||
NZ592685A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
MY180666A (en) | Substituted pyrazolo [3,4-b] pyridines as medicaments | |
GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
JP2010509356A5 (zh) | ||
NZ588830A (en) | Inhibitors of protein kinases | |
JP2010241830A5 (zh) | ||
NZ601077A (en) | Use of an adrenal hormone-modifying agent | |
RS54030B1 (en) | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT | |
WO2010007316A3 (fr) | NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET | |
WO2010089510A3 (fr) | Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique | |
JP2013542261A5 (zh) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |